A pivotal trial of Tryton Medical's side-branch stent fails to meet its non-inferiority endpoint for target vessel failure, although most of the patients in the study fell outside its target parameters.
A pivotal clinical trial of Tryton Medical's side-branch stent, the largest ever conducted on coronary bifurcation lesions, failed to meet its primary endpoint for target vessel failure.
CeQur SA is touting preliminary results from study that evaluates long-term glycemic control produced by its wearable insulin delivery device.
CeQur SA, developer of a 3-day, wearable insulin delivery device, is touting promising preliminary results from a new study evaluating its glycemic control over three months.
The Horw, Switzerland-based company, said that early data from the trial shows its PaQ device consistently improved glycemic control in patients with type 2 diabetes. That conclusion comes from a single-arm treat-to-target 12-week pilot study involving eight people with the condition.
Sequent Medical wins an FDA nod for an investigational device exemption trial of its Web aneurysm embolization device.
Sequent Medical armed itself last April with $20 million in venture cash earmarked for a U.S. IDE trial involving its Web aneurysm embolization device. Ten months later, it has the regulatory O.K. to proceed with the study.